Key result
Mean heart dose in lung cancer radiotherapy linked to ~1% higher mortality and increased cardiac events.
Why the study?
The study aimed to investigate the link between heart dose and both overall survival and cardiac events, and whether radiation-induced heart diseases associate with overall survival in lung cancer radiotherapy.
Does increased heart radiation dose increase the risk of cardiac events and worsen overall survival in lung cancer patients receiving radiotherapy?
Meta-Analysis (n=2,823)
Does increased heart radiation dose increase the risk of cardiac events and worsen overall survival in lung cancer patients receiving radiotherapy?
Effect estimate: HR 1.01 (95% CI 1.00-1.02)
Higher radiation doses to the heart during lung cancer radiotherapy are associated with increased risk of cardiac events and worse overall survival, highlighting the need to constrain heart dose.
Supports stricter heart dose constraints in lung cancer radiotherapy; reinforces cardiac exposure as a key survival determinant.
BACKGROUND: The aim of this study was to investigate the link between heart dose and overall survival, the link between heart dose and cardiac events and whether radiation-induced heart diseases were associated with overall survival in lung cancer radiotherapy. METHODS: We performed a literature search by using Pubmed, Embase, China National Knowledge Infrastructure (CNKI) databases. Pairs of reviewers independently screened literature according to the inclusion criteria, extracted data, assessed methodological quality, and publication bias. The primary end points included overall survival and cardiac events. I was calculated in a heterogeneity assessment. Publication bias was evaluated by using Begg funnel plot and Egger test. RESULTS: Ten studies including 1 randomized controlled trial, 3 post hoc analysis of prospective trials, and 6 cohort studies were identified. The meta-analysis showed that heart volume receiving ≥5 Gy (HV5) (hazard ratio [HR] = 1.01; 95% confidence interval [CI]: 1.00-1.01), heart volume receiving ≥30 Gy (HV30) (HR = 1.01; 95% CI: 1.00-1.02), heart volume receiving ≥50 Gy (HV50) (HR = 1.05; 95%CI: 1.00-1.10), and mean heart dose (MHD) (HR = 1.01; 95%CI:1.00-1.02) all were associated with worse overall survival. In addition, the MHD (HR = 1.03; 95% CI: 1.02-1.05), HV5 (HR = 1.02; 95% CI: 1.01-1.03), and HV30 (HR = 1.02; 95% CI: 1.01-1.03) were significantly associated with all grade cardiac events. Meanwhile, compared with those who did not receive radiotherapy, the radiotherapy group experienced a significantly increased risk for cardiac-specific mortality (HR = 1.297; 95% CI: 1.213-1.387). However, the results did not show that cardiac events were associated with overall survival in lung cancer radiotherapy (HR = 1.472; 95% CI: 0.988-2.193). CONCLUSION: Exposure of the heart to radiation increased the risk of cardiac events during radiotherapy for lung cancer. Meanwhile, heart dose including HV5 and HV30 were predictors of overall survival in lung cancer radiotherapy. It is necessary to constrain the heart dose when perform thoracic radiation therapy to decrease the incidence of cardiac events and improve the overall survival.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2020) conducted a meta-analysis in Lung cancer (n=2,823). Thoracic radiotherapy (heart dose exposure) vs. Lower heart dose exposure / Non-radiotherapy was evaluated on Overall survival (associated with mean heart dose) (HR 1.01, 95% CI 1.00-1.02). Mean heart dose was significantly associated with worse overall survival (HR 1.01) and an increased risk of all-grade cardiac events (HR 1.03) in patients undergoing lung cancer radiotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: